louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02457455: Urgent Medical and Surgical Conditions During Flights
Official title: Inflight Emergencies During Eurasian Flights
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Syncope
Arrest
Vertigo
Pain
Chronic Obstructive Pulmonary Disease
Hypertension
CAD
Keywords: inflight emergencies
Lead sponsor: Antalya Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2015-05-29
Enrollment: 1312
Sex: ALL
Minimum age (years): 2
Maximum age (years): 95
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All passengers who needs urgent medical support

Brief summary: The aim of this study is to evaluate the incidence and status of urgent medical conditions. After defining the urgent situations, the investigators will evaluate the adequacy of the standard medical kits and trainings.

Detailed description: In this study, the incidence and status of urgent medical conditions, the attitudes of health professionals who encounter such conditions, adequacy of Aerospace Medical Association (ASMA) suggested medical kits and training of cabin crew in data-received-company aircrafts and the demographic data of patients have been evaluated.

Eligibility criteria: Inclusion Criteria:

* All passengers (no age limitations) needed urgent medical support during flights

Exclusion Criteria:

* Patients whom medical urgency records are insufficient

Primary outcomes:
measure: Incidence of the urgent medical demands during flights
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Antalya
country: Turkey
facility: Antalya Training and Research Hospital, Department of Emergency
Study officials:
affiliation: Antalya Training and Research Hospital
name: Mustafa Kesapli, MD
role: STUDY_DIRECTOR
References:
citation: Thibeault C, Evans AD. AsMA Medical Guidelines for Air Travel: stresses of flight. Aerosp Med Hum Perform. 2015 May;86(5):486-7. doi: 10.3357/AMHP.4225.2015.
citation: Ruskin KJ. In-flight medical emergencies: time for a registry? Crit Care. 2009;13(1):121. doi: 10.1186/cc7715. Epub 2009 Feb 25.
citation: Ruskin KJ, Hernandez KA, Barash PG. Management of in-flight medical emergencies. Anesthesiology. 2008 Apr;108(4):749-55. doi: 10.1097/ALN.0b013e31816725bc. No abstract available.
citation: Lyznicki JM, Williams MA, Deitchman SD, Howe JP 3rd; Council on Sceientific Affairs, American Medical Association. Inflight medical emergencies. Aviat Space Environ Med. 2000 Aug;71(8):832-8.
Clinical trial NCT02886455: Evaluation of the Influence of Output on Skin Covered by Newly Developed Adhesives
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ileostomy - Stoma
Lead sponsor: Coloplast A/S
Sponsor class: INDUSTRY
First posted: 2016-09-01
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The study investigates the impact real output has on peristomal skin covered by a newly developed adhesive and a standard adhesive.


Eligibility criteria: Inclusion Criteria:

1. Have given written informed consent
2. Be at least 18 years of age and have full legal capacity
3. Have had an ileostomy for more than one year
4. Have intact skin on the area used in the evaluation
5. Has an ileostomy with a diameter up to (≤) 35 mm
6. Have a peristomal area accessible for application of patches/adhesive strips (assessed by investigating scientist)

Exclusion Criteria:

1. Currently receiving or have within the past 2 month received radio- and/or chemotherapy
2. Currently receiving or have within the past month received topical steroid treatment in the peristomal skin area or systemic steroid (tablet/injection) treatment.
3. Are pregnant or breastfeeding
4. Having dermatological problems in the peristomal- or abdominal area (assessed by investigating scientist)
5. Participating in other interventional clinical investigations or have previously participated in this evaluation

Primary outcomes:
measure: Trans epidermal water loss
timeFrame: 4-24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Humlebaek
country: Denmark
facility: Coloplast A/S
Study officials:
affiliation: R&D scientist
name: Lene F Nielsen, Msc
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02456155: A Trial of Bedside Placement of Nasal Jejunal Tube Confirmed by Ultrasound Compared to Placement by Endoscope in Patients With SAP
Official title: Study to Compare the Placement Method of Nasal Jejunal Tube in Patients With Severe Acute Pancreatitis: Bedside Placement With Ultrasound Confirmation Versus Placement Endoscopically
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Bedside Placement of Nasal Jejunal Tube
Keywords: bedside placement
nasal jejunal tube
ultrasound
severe acute pancreatitis
endoscope
efficacy
safety
Lead sponsor: Nanjing University
Sponsor class: OTHER
First posted: 2015-05-28
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators assessed the utility of ultrasonography in confirming the position of nasal jejunal tube after bedside placement when compared with endoscopic placement in patients with severe acute pancreatitis.

Primary endpoint:

Success rate.

Secondary Endpoint:

Adverse effects, Change of intra-abdominal pressure (1h before, 1h after and 3 days after placement), Tolerance of enteral nutrition, Time to approach the target calories.

Detailed description: We set this randomised trial to assess the safety and utility of ultrasonography in confirming the position of nasal jejunal tube after bedside placement when compared with endoscopic placement in patients with severe acute pancreatitis.

Primary endpoint:

Success rate.

Secondary Endpoint:

Adverse effects, Change of intra-abdominal pressure (1h before, 1h after and 3 days after placement), Tolerance of enteral nutrition, Time to approach the target calories.

Eligibility criteria: Inclusion Criteria:

* acute pancreatitis patients who need enteral nutrition;
* patients in acute phase of pancreatitis (within 2 weeks from onset);
* the severity of pancreatitis is equal to or above moderate (according to the revised classification of pancreatitis).

Exclusion Criteria:

* diagnosed with IAH(Intra-abdominal pressure) IV grade, abdominal compartment syndrome (ACS);
* patients who have circulatory failure;
* patients who have gastrointestinal bleeding;
* patients who have specific diseases such as chronic digestive diseases and autoimmune diseases;
* patients in pregnancy.

Primary outcomes:
measure: Success rate
timeFrame: 24 hours
Secondary outcomes:
measure: Adverse effects
timeFrame: 24 hours
measure: Change of intra-abdominal pressure
timeFrame: 3 days
measure: Tolerance of enteral nutrition
timeFrame: 3 days
measure: Time interval to approach the target calories
timeFrame: 7 days
Other outcomes:
Locations:
city: Nanjing
country: China
facility: JinLing hospital
state: Jiangsu
Study officials:
References:
Clinical trial NCT03840655: Fluorescent Thoracoscopy Used in Surgery for Palmar Hyperhidrosis
Official title: Fluorescent Thoracoscopy Used in Surgery for Palmar Hyperhidrosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Palmar Hyperhidrosis
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
Collaborators: name: Beijing Municipal Science & Technology Commission
First posted: 2019-02-15
Enrollment: 89
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients suffering from primary palmar hyperhidrosis

Brief summary: T3/T4 endoscopic thoracic sympathicotomy is a widely accepted and effective treatment for primary palmar hyperhidrosis. However, sympathetic ganglions are invisible with traditional thoracoscopy and until now, the location of ganglions are confirmed by rib indirectly. The team from thoracic department of Peking University People's Hospital discovered that the sympathetic ganglions can be visualized with fluorescent thoracoscopy. Thus, investigators want to apply fluorescent thoracoscopy in sympathicotomy of palmar hyperhidrosis, to conduct a more precise operation and compare the efficiency of the novel and traditional methods.


Eligibility criteria: Inclusion Criteria:

1. Diagnosed with primary palmar hyperhydrosis.
2. Accept surgical treatment and signed informed consent.

Exclusion Criteria:

1. Liver dysfunction.
2. Allergic to indocyanine green.
3. Can't tolerate thoracoscopic surgery.

Primary outcomes:
measure: Anatomical variation of the sympathetic ganglions
timeFrame: during surgery
Secondary outcomes:
measure: Improvement of palmar sweating
timeFrame: 1 month after surgery
measure: Degree of compensatory hyperhidrosis
timeFrame: 1 month after surgery
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People'S Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT01556555: Clinical Utility of the Spyglass System in Primary Sclerosing Cholangitis (PSC)
Official title: Prospective Evaluation of the Clinical Utility of Peroral Cholangiopancreatoscopy With the Spyglass System in Patients With Sclerosing Cholangitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sclerosing Cholangitis
Keywords: Sclerosing cholangitis
Spyglass
Endoscopic retrograde cholangiopancreaticography
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2012-03-16
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with SC, sclerosing cholangitis, who is undergoing ERCP, (Endoscopic Retrograde Cholangio and Pancreaticography)

Brief summary: This study aim to prospectively evaluate the clinical utility of Spyglass in sclerosing cholangitis patients undergoing endoscopic retrograde cholangiopancreaticography (ERCP). Fifty patients with a definite diagnosis of sclerosing cholangitis and a clinical indication for ERCP from September 2008 and onwards will be investigated with peroral cholangioscopy using Spyglass direct visualization system. Clinical data on all patients will be collected at time of the ERCP including information on the Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), serum liver function tests and indication for ERCP.

A structured data collection form including information on Majoie Score, macroscopic features of the bile ducts at cholangioscopy, quality of the investigation, technical difficulties, and an overall judgment of whether any abnormalities observed were benign or malignant was completed by the endoscopist in conjunction with the procedure.


Eligibility criteria: Inclusion Criteria:

* sclerosing cholangitis with indication for ERCP
* Over 18 year
* informed consent

Exclusion Criteria:

* Not able to sign informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University Hospital, Huddinge
Study officials:
affiliation: Karolinska University Hospital
name: Annika Bergquist, Assoc prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Arnelo U, von Seth E, Bergquist A. Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. Endoscopy. 2015 Aug;47(8):696-702. doi: 10.1055/s-0034-1391845. Epub 2015 Mar 31.
Clinical trial NCT03982355: Development and Validation of a Tumour Oxygenation Monitoring Probe
Official title: Development and Validation of a Tumour Oxygenation Monitoring Probe
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cancer
Keywords: Cancer
Lead sponsor: Imperial College London
Sponsor class: OTHER
First posted: 2019-06-11
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pretreatment anonymised MRIs from (locally advanced) breast and rectal cancer sufferers

Brief summary: Laboratory based study in which novel tissue oxygenation probe with the potential provide novel means for assessing response to cancer treatment will be developed and validated.

Detailed description: Tumour hypoxia is feature common to most solid tumours, with significant implications in tumour aggressiveness, metastatic potential and response to therapy. Tumour oxygenation monitoring is likely, therefore, to provide a valuable adjunct in risk stratification and treatment response monitoring.

Diffuse reflectance spectroscopy (DRS) utilises the differing absorption of oxygenated as compared to deoxygenated haemoglobin to provide an accurate measure of tissue oxygenation.

This project aims to develop and validate a tissue oxygenation probe for cancer monitoring. Using the clinical paradigms of rectal and breast cancer, anonymised MRIs of cancer sufferers will guide simulations of tissue optical properties to develop a DRS probe. The 3D reconstructed sans will then be used to 3D print tissue phantom models on which the DRS probe will be validated against reference bench top analysers.

Eligibility criteria: Inclusion Criteria:

* MRIs from Breast or Rectal Cancer patients (10 of each)
* Locally advanced Cancers (Stage 2 or 3)
* Patients who went on to receive neoadjuvant chemoradiotherapy.
* Anonymised scans

Exclusion Criteria:

* MRIs from patients under the age of 18, or older than 99 years old will be excluded.
* MRIs from patients who did not receive neoadjuvant therapy for cancer will be excluded.

Primary outcomes:
measure: Count of MRIs Successfully Modelled for Oxygen Correlation
timeFrame: MRIs were 3D modelled - single time point at time of MRI
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Imperial College London
state: Greater London
Study officials:
affiliation: Imperial College London
name: Ara Darzi
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06233955: Effect of Maitland Mobilization With Low Level Laser Therapy in Treatment of Patients With Knee Osteoarthritis
Official title: Effect of Maitland Mobilization With Low Level Laser Therapy in Treatment of Patients With Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Knee Osteoarthritis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-01-31
Enrollment: 75
Sex: ALL
Minimum age (years): 50
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Background: Osteoarthritis is a common cause of chronic pain and disability in elderly people.

Objective: To evaluate the efficacy of low-level laser therapy (LLLT) in combination with Maitland mobilization and conventional physical therapy in patients with chronic knee osteoarthritis.

Design: Pre-test post-test randomized control trial.

Detailed description: Knee OA is associated with pain and disability, high treatment costs, decreased productivity, and absence from work and thus has a substantial and growing burden on society Objective: To evaluate the efficacy of low-level laser therapy (LLLT) in combination with Maitland mobilization and conventional physical therapy in patients with chronic knee osteoarthritis.

Participants: Seventy five subjects of both genders with age range from 50 to 65 years, with proven bilateral knee OA diagnosed and referred by orthopaedist were recruited for the study and randomly assigned into three groups.

Eligibility criteria: Inclusion Criteria:

Subjects with proven bilateral Knee OA with age range 50- 65 years according to the American College of Rheumatology criteria.

2- Only patients with X-ray stages II and III osteoarthritis selected according to Kellgren \& Lawrence classification system.

3- BMI equal to or less than 30 . 4- Patients with Knee pain lasted at least 6 months with intensity at least 3 on VAS scale in activities such as going up-and downstairs, sitting and squatting.

5- Patients with normal mental state. 6- Patients who are not participating in physical therapy in the recent 3 months.

.

Exclusion Criteria:

1. Patient with history of gout, infection, tumour, autoimmune diseases, trauma or other causes of knee pain or knee deformities.
2. Patient with neurologic dysfunction, or with history of chronic disease that may affect the study.
3. Patient with history of knee intra-articular injection in the past 6 months.

Primary outcomes:
measure: Visual analogue scale
timeFrame: Four weeks
measure: Pressure Algometer
timeFrame: Four weeks
measure: Knee digital goniometry
timeFrame: Four weeks
Secondary outcomes:
measure: Knee injury and osteoarthritis outcome score short form
timeFrame: Four weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of physical therapy Cairo university
state: Dokki
Study officials:
References:
Clinical trial NCT02567955: Immunogenicity and Safety of Gardasil-9 and Cervarix
Official title: Immunogenicity and Safety of Gardasil-9 and Cervarix When Administered to 9-10-year-old Subjects According to 0-6 Month Schedule
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: HPV Vaccines Immunogenicity and Safety
Keywords: HPV vaccines, interchangeable use
Lead sponsor: Laval University
Sponsor class: OTHER
First posted: 2015-10-05
Enrollment: 376
Sex: ALL
Minimum age (years): 9
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: A ninevalent HPV vaccine (Gardasil-9) has been recently approved for clinical use. No data on immunogenicity and safety of interchangeable use of the ninevalent and the bivalent vaccine (Cervarix) are available. The main objective of this study is to assess the immunogenicity of ninevalent and bivalent HPV vaccines when administered to 9-10-year-old girls and boys according to 0-6 month schedule.

Detailed description: The proportion of subjects with detectable antibodies and antibody geometrical mean titers to 9 HPV genotypes included in the Gardasil-9 vaccine will be assessed 1 and 6 months post-first dose and 1, 18 and 36 months post-second dose of vaccine.

Eligibility criteria: Inclusion Criteria:

* 9-10-year-old girls and boys

Exclusion Criteria:

* previously received an HPV vaccine
* immunosuppressed
* known allergy to a vaccine component

Primary outcomes:
measure: Comparison of proportion of subjects with detectable antibodies to 9 HPV genotypes included in the Gardasil-9 vaccine observed in two study arms
timeFrame: 36 months post-second dose of vaccine
Secondary outcomes:
measure: Comparison of tolerability profile of Gardasil-9 and Cervarix
timeFrame: During 5 days after each vaccine dose administration.
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: Équipe de recherche en vaccination
Study officials:
References:
citation: Gilca V, Sauvageau C, Panicker G, De Serres G, Schiller J, Ouakki M, Unger ER. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials. Hum Vaccin Immunother. 2019;15(7-8):1980-1985. doi: 10.1080/21645515.2019.1605278. Epub 2019 Jun 3.
citation: Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018 Nov 12;36(46):7017-7024. doi: 10.1016/j.vaccine.2018.09.057. Epub 2018 Oct 9.
Clinical trial NCT00309855: Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
Official title: Mechanisms of Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men: Modulation of GHRH, GHRP and Somatostatin Action by Estrogenic Versus Androgenic Steroids
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Aging
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2006-04-03
Enrollment: 80
Sex: MALE
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study is being done to understand how testosterone, the major male sex hormone, controls the pituitary gland's secretion of growth hormone (GH). GH is an important metabolic hormone, which controls sugar; fat and protein use in the body and maintains muscle strength and bone calcium content. Both testosterone and GH decline in older men. The age-related fall in these hormones probably contributes to relative frailty, reduced quality of life, bone loss, muscle wasting and impaired sexual function.

Detailed description: Repletion of testosterone in older men drives pulsatile GH secretion via conjoint facilitation of feedforward by the primary secretagogues GHRH and GHRP and repression of feedback by the dominant inhibitor, somatostatin; and, in corollary, testosterone acts via aromatization to estradiol and/or reduction to 5 alpha-dihydrotestosterone

Eligibility criteria: Inclusion Criteria:

* healthy men between the ages of 50 and 80;
* normal weight (within 30% of ideal body weight defined by New York Metropolitan Life tables); and
* normal hematocrit (greater than 38%);
* community dwelling; and
* voluntarily consenting

Exclusion Criteria:

* recent use of psychotropic or neuroactive drugs (within five biological half-live);
* obesity (outside weight range above);
* anemia (hematocrit \< 38%);
* drug or alcohol abuse, psychosis, depression, mania or severe anxiety;
* acute or chronic organ-system disease;
* endocrinopathy, other than primary thyroidal failure receiving replacement;
* nightshift work or recent transmeridian travel (exceeding 3 time zones within 7 days of admission);
* acute weight change (loss or gain of \> 2 kg in 6 weeks);
* allergy to administered compounds; and
* unwillingness to provide written informed consent.

Primary outcomes:
measure: Growth Hormone concentration after injections
timeFrame: 24 days
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Johannes D. Veldhuis, M.D.
role: PRINCIPAL_INVESTIGATOR
References: